LEXINGTON, Mass.–(BUSINESS WIRE)– AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and Chief Executive Officer, will present an overview of the Company at the Canaccord Adams 29th Annual Global Growth Conference on Tuesday, August 11 at 9:00 a.m. ET. The conference is being held August 11-13, 2009 in Boston, MA. A live audio webcast of the presentation will be accessible through the Investors section of the Company’s website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until August 25, 2009. About AMAG Pharmaceuticals, Inc. AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. AMAG recently received approval from the U.S. Food and Drug Administration to market Feraheme(TM) (ferumoxytol) Injection for the treatment of iron deficiency anemia in adult chronic kidney disease patients. For additional company and product information please visit www.amagpharma.com. Feraheme(TM) is a trademark of AMAG Pharmaceuticals, Inc. Source: AMAG Pharmaceuticals, Inc. Contact: AMAG Pharmaceuticals, Inc. Carol Miceli, 617-498-3361 | |
As of November, 2020 AMAG Pharmaceuticals, Inc. is now a subsidiary of the Covis Pharma Group. For more information about Covis, please visit (covispharma.com)
